Innate inflammation in myocardial perfusion and its implication for heart failure

Annals of the New York Academy of Sciences

Volumn 1207, Issue , 2010, Pages 107-115

  Picano, Eugenio ^a   Morales, Maria Aurora ^a   del Ry, Silvia ^a   Sicari, Rosa ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Contractile reserve; Coronary flow reserve; Heart failure

Indexed keywords

ADENOSINE; AUTOANTIBODY; DILAZEP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ENDOTOXIN; HEAT SHOCK PROTEIN; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROHORMONE; TUMOR NECROSIS FACTOR ALPHA; AUTACOID;

ARTICLE; AUTOIMMUNITY; CARDIOMYOPATHY; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; EXERCISE; HEART DISEASE; HEART EJECTION FRACTION; HEART FAILURE; HEART INJURY; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART MUSCLE PERFUSION; HYPERTENSION; INFLAMMATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; SHEAR STRESS; BIOLOGICAL MODEL; CORONARY ARTERY BLOOD FLOW; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; MICROCIRCULATION; PHENOTYPE; PHYSIOLOGY; PROGNOSIS; REVIEW; VASCULAR ENDOTHELIUM;

CORONARY CIRCULATION; ENDOTHELIUM, VASCULAR; HEART FAILURE; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INFLAMMATION MEDIATORS; MICROCIRCULATION; MODELS, CARDIOVASCULAR; PHENOTYPE; PROGNOSIS;

EID: 78149260662     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05724.x     Document Type: Article

References (51)

1. Schocken, D.D., E.J. Benjamin, G.C. Fonarow, et al. 2008. Prevention of heart failure: a scientific statement from the AmericanHeart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology InterdisciplinaryWorking Group. Circulation 117: 2544-2565.
2. Redfield, M.M., S.J. Jacobsen, J.C. Burnett Jr., et al. 2003. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289: 194-202.
3. Hunt, S.A., W.T. Abraham, M.H. Chin, et al. American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. 2005. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112: e154-e235.
4. Mann, D.L. 2002. Inflammatory mediators and the failing heart: past, present and the foreseeable future. Circ. Res. 91: 988-998.
5. Hedayat, M., M.J. Mahmoudi, N.R. Rose & N. Rezaei. 2010. Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail. Rev. [Epub ahead of print].
6. Levine, B., J. Kalman, L. Mayer, et al. 1990. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.N. Engl. J. Med. 323: 236-241.
7. Rauchhaus, M., W. Doehner & D.P. Francis. 2000. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102: 3060-3067.
8. Torre-Amione,G., S.Kapadia,C.Benedict, et al. 1996.Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J. Am. Coll. Cardiol. 27: 1201-1206.
9. Yndestad, A., J.K. Damås, E. Oie, et al. 2006. Systemic inflammation in heart failure-thewhys andwherefores.Heart Fail. Rev. 11: 83-92.
10. Seta, Y., K. Shan, B. Bozkurt, et al. 1996. Basic mechanisms in heart failure: the cytokine hypothesis. J. Card. Fail. 2: 243-249.
11. Heymans, S., E. Hirsch, S.D. Anker, et al. 2009. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 11: 119-129.
12. Tousoulis, D., M. Charakida & C. Stefanadis. 2005. Inflammation and endothelial dysfunction as therapeutic targets in patients with heart failure. Int. J. Cardiol. 100: 347-353.
13. Colombo, P.C., J.E. Banchs, S. Celaj, et al. 2005. Endothelial cell activation in patients with decompensated heart failure. Circulation 111: 58-62.
14. Celermajer, D.S. 1997. Endothelial dysfunction: does itmatter? Is it reversible? J. Am. Coll. Cardiol. 30: 325-333.
15. Agnoletti, L., S. Curello, T. Bachetti, et al. 1999. Serumfrom patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-alpha. Circulation 100: 1983-1991.
16. Roman, M.J., T.Z. Naqvi, J.M. Gardin, et al. American Society of Echocardiography; Society for Vascular Medicine and Biology. 2006. American Society of Echocardiography report. Clinical application of noninvasive vascular ultrasound in cardiovascular risk stratification: a report from the American Society of Echocardiography and the Society for Vascular Medicine and Biology. Vasc. Med. 11: 201-211.
17. Katz, S.D., L. Biasucci, C. Sabba, et al. 1992. Impaired endothelium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failure. J. Am. Coll. Cardiol. 19: 918-925.
18. Kubo, S.H., T.S. Rector, A.J. Bank, et al. 1991. Endotheliumdependent vasodilation is attenuated in patients with heart failure. Circulation 84: 1589-1596.
19. Nakamura, M., S. Sugawara, N. Arakawa, et al. 2004. Reduced vascular compliance is associated with impaired endothelium-dependent dilatation in the brachial artery of patientswith congestive heart failure. J. Card. Fail. 10: 36-42.
20. Drexler, H., D. Hayoz, T. Munzel, et al. 1992. Endothelial function in chronic congestive heart failure. Am. J. Cardiol. 69: 1596-1601.
21. Katz, S.D., K. Hryniewicz, I. Hriljac, et al. 2005. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 111: 310-314.
22. Meyer, B., D. Mortl, K. Strecker, et al. 2005. Flow-mediated vasodilation predicts outcome in patientswith chronic heart failure: comparison with B-type natriuretic peptide. J. Am. Coll. Cardiol. 46: 1011-1018.
23. Shah, A., E. Gkaliagkousi, J.M. Ritter & A. Ferro. 2010. Endothelial function and arterial compliance are not impaired in subjects with heart failure of non-ischemic origin. J. Card. Fail. 16: 114-120.
24. Anderson, T.J., A. Uehata, M.D. Gerhard, et al. 1995. Close relation of endothelial function in the human coronary and peripheral circulations. J. Am. Coll. Cardiol. 26: 1235-1241.
25. Stolen, K.Q., J. Kemppainen, K.K. Kalliokoski, et al. 2004. Myocardial perfusion reserve and peripheral endothelial function in patients with idiopathic dilated cardiomyopathy. Am. J. Cardiol. 93: 64-68.
26. Marcus, M.L. 1983. The Coronary Circulation in Health and Disease. 65-92. McGraw Hill. New York.
27. Tsagalou, E.P., M. Anastasiou-Nana, E. Agapitos, et al. 2008. Depressed coronary flowreserve is associatedwith decreased myocardial capillary density in patients with heart failure due to idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. 52: 1391-1398.
28. Camici, P.G. & F. Crea. 2007. Coronary microvascular dysfunction. N. Engl. J. Med. 356: 830-840.
29. Rigo, F., B. Murer, G. Ossena & E. Favaretto. 2008. Transthoracic echocardiographic imaging of coronary arteries: tips, traps, and pitfalls. Cardiovasc. Ultrasound 6: 7.
30. Neglia, D., O. Parodi, M. Gallopin, et al. 1995. Myocardial blood flow response to pacing tachycardia and to dipyridamole infusion in patients with dilated cardiomyopathy without overt heart failure. A quantitative assessment by positron emission tomography. Circulation 92: 796-804.
31. Neglia, D., C. Michelassi,M.G. Trivieri, et al. 2002. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 105: 186-193.
32. Rigo, F., S. Gherardi, M. Galderisi, et al. 2006. The prognostic impact of coronary flow-reserve assessed by Doppler echocardiography in non-ischaemic dilated cardiomyopathy. Eur. Heart J. 27: 1319-1323.
33. Dini, F.L., L. Ghiadoni, U. Conti, et al. 2009. Coronary flow reserve in idiopathic dilated cardiomyopathy: relation with left ventricularwall stress, natriuretic peptides, and endothelial dysfunction. J. Am. Soc. Echocardiogr. 22: 354-360.
34. Giannessi, D., C. Colotti, M. Maltinti, et al. 2007. Circulating heat shock proteins and inflammatory markers in patients with idiopathic left ventricular dysfunction: their relationships with myocardial and microvascular impairment. Cell Stress Chaperones 12: 265-274.
35. Giannessi, D., C. Caselli, S. Del Ry, et al. 2010. Adiponectin is associated with abnormal lipid profile and coronary microvascular dysfunction in patients with dilated cardiomyopathy without overt heart failure. Metabolism [Epub ahead of print].
36. Torres, M.A., E. Picano, G. Parodi, et al. 1997. Flow-function relation in patients with chronic coronary artery disease and reduced regional function. A positron emission tomographic and two-dimensional echocardiographic study with coronary vasodilator stress. J. Am. Coll. Cardiol. 30: 65-70.
37. Picano, E., R. Sicari, P. Landi, et al. 1998. Prognostic value of myocardial viability in medically treated patientswith global left ventricular dysfunction early after an acute uncomplicated myocardial infarction: a dobutamine stress echocardiographic study. Circulation 98: 1078-1084.
38. Sicari, R., A. Ripoli, E. Picano, et al. VIDA (Viability Identification with Dipyridamole Administration) Study Group. 2001. The prognostic value of myocardial viability recognized by low dose dipyridamole echocardiography in patients with chronic ischaemic left ventricular dysfunction. Eur. Heart J. 22: 837-484.
39. Ciampi, Q., L. Pratali, R. Citro, et al. 2009. Identification of responders to cardiac resynchronization therapy by contractile reserve during stress echocardiography. Eur. J. Heart Fail. 11: 489-496.
40. Pratali, L., P. Otasevic, A. Neskovic, et al. 2007. Prognostic value of pharmacologic stress echocardiography in patients with idiopathic dilated cardiomyopathy: a prospective, headto-head comparison between dipyridamole and dobutamine test. J. Card. Fail. 13: 836-842.
41. Fischer-Rasokat, U., B. Assmus, F.H. Seeger, et al. 2009. A pilot trial to assess potential effects of selective intracoronary bone marrow-derived progenitor cell infusion in patients with nonischemic dilated cardiomyopathy: final 1-year results of the transplantation of progenitor cells and functional regeneration enhancement pilot trial in patients with nonischemic dilated cardiomyopathy. Circ. Heart Fail. 2: 417-423.
42. Kitakaze, M., T. Minamino, K. Node, et al. 1998. Elevation of plasma adenosine levelsmay attenuate the severity of chronic heart failure. Cardiovasc. Drugs Ther. 12: 307-309.
43. Sanada, S., H. Asanuma, Y. Koretsune, et al. 2007. Longterm oral administration of dipyridamole improves both cardiac and physical status in patientswith mild to moderate chronic heart failure: a prospective open randomized study. Hypertens. Res. 30: 913-919.
44. Akhtar, M., K. Ordovas, A. Martin, et al. 2007. Effect of chronic sustained release dipyridamole onmyocardial blood flow and left ventricular function in patients with ischemic cardiomyopathy. Congest. Heart Fail. 13: 130-135.
45. Picano, E. & C. Michelassi. 1997. Chronic oral dipyridamole as a 'novel' antianginal drug: the collateral hypothesis. Cardiovasc. Res. 33: 666-670.
46. Ryzhov, S., N.V. Solenkova, A.E. Goldstein, et al. 2008. Adenosine receptor-mediated adhesion of endothelial progenitors to cardiacmicrovascular endothelial cells. Circ. Res. 102: 356-363.
47. Torry, R.J., D.M. O'Brien, P.M. Connell, et al. 1992. Dipyridamole-induced capillary growth in normal and hypertrophic hearts. Am. J. Physiol. 262: H980-H986.
48. Belardinelli, R., L. Belardinelli & J.C. Shryock. 2001. Effects of dipyridamole on coronary collateralization and myocardial perfusion in patients with ischaemic cardiomyopathy. Eur. Heart J. 22: 1205-1213.
49. Picano, E. 2001. Dipyridamole in chronic stable angina. A randomized, double blind, placebo-controlled, parallel group study. Eur. Heart J. 22: 1785-1793.
50. Jagathesan, R., S.D. Rosen, R.A. Foale, et al. 2006. Effects of long-term oral dipyridamole treatment on coronary microcirculatory function in patients with chronic stable angina: a substudy of the persantine in stable angina (PISA) study. J. Cardiovasc. Pharmacol. 48: 110-116.
51. Swedberg, K., J. Cleland, H. Dargie, et al. Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. 2005. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur. Heart J. 26: 1115-1140.